Science News | Study Shows Anti-inflammatory Medicine as a Promising Target for Alzheimer's Disease
Get latest articles and stories on Science at LatestLY. This study concentrated on the protein p38. Many labs have been studying this protein as a potential target for medication development to treat Alzheimer's disease and other neuroinflammatory disorders.
Washington DC [US], July 18 (ANI): Linda Van Eldik, PhD, Director of the University of Kentucky's Sanders-Brown Centre on Ageing, recently published a paper in PLOS ONE.
The study is based on the hypothesis that several anti-inflammatory medications could be effective treatments for Alzheimer's disease (AD).
Also Read | Heartbeat: 5 Times Won Ji An Proves She Is Unlike A Korean Rom-Com Heroine.
This study concentrated on the protein p38. Many labs have been studying this protein as a potential target for medication development to treat Alzheimer's disease and other neuroinflammatory disorders.
Van Eldik and her team used genetic techniques to stop the production of p38 in the major immune cell type within the brain, the microglia. They tested the effects of this in an early-stage mouse model of AD to determine whether it would alter the trajectory of amyloid plaque formation, a major component of AD pathology.
Also Read | PV Sindhu Drops to World No. 17, Lowest Ranking Since January 2013.
While the plaques themselves were not affected, the amount of microglia in proximity to these plaques was decreased, suggesting that suppression of microglial p38 may affect their interactions with aspects of AD pathology.
Some classes of anti-inflammatory drugs include p38 inhibitors, which are currently under clinical development and have shown encouraging results during recent human clinical trials.
However, it is still not clear when during the disease process these p38 inhibitors should be administered and whether long-term suppression of p38 is harmful.
The findings reported by the Van Eldik lab indicate that early inhibition of p38 may be able to alter interactions between brain immune cells and AD pathology, and they suggest that long-term suppression of p38 does not cause noticeable adverse effects. (ANI)
(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)